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Rapamycin,  an  inhibitor  of  mTOR  activity,  is  a  potent  inducer  of  erythroid  differentiation  and  fetal
hemoglobin  production  in  -thalassemic  patients.  Mithramycin  (MTH)  was  studied  to  see  if  this  inducer
of  K562  differentiation  also  operates  through  inhibition  of mTOR.  We  can  conclude  from  the  study  that
the  mTOR  pathway  is among  the  major  transcript  classes  affected  by mithramycin-treatment  in  K562
cells  and  a sharp  decrease  of raptor  protein  production  and  p70S6  kinase  is detectable  in mithramycin
treated  K562  cells.  The  promoter  sequence  of  the  raptor  gene  contains  several  Sp1  binding  sites  which may
explain its mechanism  of  action.  We hypothesize  that  the G +  C-selective  DNA-binding  drug  mithramycin
is  able  to interact  with  these  sequences  and  to  inhibit  the binding  of  Sp1  to  the  raptor  promoter  due  to
the  following  results:  (a)  MTH  strongly  inhibits  the  interactions  between  Sp1  and  Sp1-binding  sites  of
the raptor  promoter  (studied  by  electrophoretic  mobility  shift  assays,  EMSA);  (b)  MTH  strongly  reducesTOR
p1
ithramycin
rythroid induction
etal hemoglobin
the  recruitment  of  Sp1  transcription  factor  to  the  raptor  promoter  in  intact  K562  cells (studied  by chro-
matin  immunoprecipitation  experiments,  ChIP);  (c) Sp1  decoy  oligonucleotides  are  able  to  speciﬁcally
inhibit  raptor  mRNA  accumulation  in  K562  cells.  In  conclusion,  raptor  gene  expression  is involved  in
mithramycin-mediated  induction  of erythroid  differentiation  of  K562  cells  and  one  of its mechanism  of
action  is  the  inhibition  of Sp1  binding  to the  raptor  promoter.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-NDntroduction
The mammalian target of rapamycin (mTOR) forms two  com-
lexes, named mTOR complex 1 (mTORC1) and mTOR complex
 (mTORC2) which are regulated by phosphorylation, complex
ormation and localization within the cells [1–5]. mTORC1 is com-
osed of mTOR, the regulatory associated protein of mTOR (raptor),
Abbreviations: Raptor, regulatory associated protein of mTOR; Rictor,
apamycin-insensitive companion of mTOR; mTOR, mammalian target of
apamycin; mTORC1, mTOR complex 1; m-TORC2, mTOR complex 2; Sp1, speciﬁc
rotein 1; MTH, mithramycin; RAPA, rapamycin; ChIP, chromatin immunoprecip-
tation; EMSA, electrophoretic mobility shift assay; FBS, fetal bovine serum; PBS,
hosphate-buffered saline; TBS, tris-buffered saline; HbF, fetal hemoglobin; ODN,
ligonucleotide.
∗ Corresponding author at: Department of Life Sciences and Biotechnology, Molec-
lar Biology Section, University of Ferrara, Via Fossato di Mortara 74, 44121 Ferrara,
taly. Tel.: +39 532 974443; fax: +39 532 974500.
E-mail address: gam@unife.it (R. Gambari).
ttp://dx.doi.org/10.1016/j.phrs.2014.11.005
043-6618/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
mammalian LST8/G-protein -subunit like protein (mLST8/GL)
and the recently identiﬁed partners PRAS40 and DEPTOR [6,7].
Raptor binds directly to mTOR signaling (TOS) motifs on down-
stream targets, including S6K1 (ribosomal S6 protein kinase 1)
and 4EBP1 (eukaryotic initiation factor 4E-binding protein 1)
as well as PRAS40 and Hif1, thus linking them to the mTOR
kinase [2,3]. mTORC1 senses and integrates diverse extra- and
intracellular signals to promote anabolic and to inhibit catabolic
cellular processes. This complex is characterized by the classic fea-
tures of mTOR by functioning as a nutrient/energy/redox sensor
and controlling protein synthesis [1,6]. The activity of this com-
plex is stimulated by insulin, growth factors, serum, phosphatidic
acid, amino acids (particularly leucine), and oxidative stress [6,8].
mTORC1 in yeast and mammals also promotes “ribosome biogen-
esis”, a process whereby mTORC1 increases the transcription of
ribosomal RNAs and proteins to augment cellular protein biosyn-
thetic capacity [9–11]. mTOR Complex 2 (mTORC2) is composed of
mTOR, rapamycin-insensitive companion of mTOR (Rictor), GL,
and mammalian stress-activated protein kinase interacting pro-
tein 1 (mSIN1) [2,3,12,13]. mTORC2 has been shown to function
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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s an important regulator of the cytoskeleton through its stimula-
ion of F-actin stress ﬁbers, paxillin, RhoA, Rac1, Cdc42, and protein
inase C  (PKC) [14–17]. mTORC2 also appears to possess the
ctivity of a previously elusive protein known as “PDK2.” mTORC2
hosphorylates the serine/threonine protein kinase Akt/PKB at a
erine residue S473. Phosphorylation of the serine stimulates Akt
hosphorylation at a threonine T308 residue by PDK1 and leads
o full Akt activation [13,16,17]; mTORC2 appears to be regulated
y insulin, growth factors, serum, and nutrient levels [6,7]. Origi-
ally, mTORC2 was identiﬁed as a rapamycin-insensitive entity, as
cute exposure to rapamycin did not affect mTORC2 activity or Akt
hosphorylation. However, subsequent studies have shown that,
t least in some cell lines, chronic exposure to rapamycin, while
ot affecting pre-existing mTORC2s, promotes rapamycin bind-
ng to free mTOR molecules, thus inhibiting the formation of new
TORC2 [14].
Despite the fact that the involvement of mTOR in all these
nd other biological processes has been ﬁrmly established, little
nformation is available on the role of mTOR on erythroid differ-
ntiation. It has been demonstrated that rapamycin, an inhibitor
f mTOR activity, is a potent inducer of erythroid differentiation of
uman leukemic K562 cells [18] and fetal hemoglobin production
y -thalassemic patients [19]. Accordingly, other inducers of K562
ifferentiation might operate through inhibition of mTOR [20–22].
n order to address this issue, mithramycin (MTH) was  studied. This
NA-binding low molecular weight molecule is selective for G + C
ich regions [23–25]. It binds to the minor groove of DNA generat-
ng unstable MTH-DNA complexes [20]. It is one of the most potent
nducers of K562 differentiation [21] and HbF production by ery-
hroid precursor cells from normal donors as well as -thalassemia
atients [26].
The main objective of the present study was to verify whether
nduction of differentiation by MTH  is associated with inhibition of
TOR activity. The effects of MTH  on raptor, rictor and mTOR gene
xpression were ﬁrst analyzed by q-RT-PCR. Secondly, we deter-
ined by Western blotting, the production of mTOR, raptor and
ictor proteins in MTH  treated cells with the aim of determining
hether mithramycin affects mTORC1, mTORC2 or both. Thirdly,
e veriﬁed the possible effect of MTH  on the interaction of the
egulatory transcription factor Sp1 with the raptor promoter. This
as approached by electrophoretic mobility shift assay, chromatin
mmunoprecipitation and treatment of target cells with Sp1 decoy
olecules.
aterials and methods
uman K562 cell cultures
The human leukemia K562 [27,28] cells were cultured in a
umidiﬁed atmosphere of 5% CO2/air in RPMI 1640 medium
SIGMA, St. Louis, MO,  USA) supplemented with 10% (vol/vol) fetal
ovine serum (FBS; Biowest, Nuaille, F), 100 U/ml penicillin, and
00 g/ml streptomycin. Cell growth was studied by determining
he cell number per ml  with a Z2 Coulter Counter (Beckman Coulter,
ullerton, CA, USA).
ntibodies
The primary antibodies for Western blotting were: anti-Raptor
at. 2280, anti-Rictor cat. 2114, anti-mTOR cat. 2983, anti-p-mTOR
Ser2448) cat. 2971, anti-p-mTOR (Ser2481) cat.2974, anti-p70S6
inase cat.2708, anti-p-p70S6 kinase (Thr389) cat.9234. All anti-
odies were purchase from Cell Signaling (Euroclone S.p.A., Pero,
I,  Italy). Research 91 (2015) 57–68
RNA extraction
Cells were isolated by centrifugation at 1500 rpm for 10 min
at 4 ◦C, washed in PBS, lysed in Tri-reagentTM (Sigma–Aldrich,
St. Louis, MO,  USA), according to the manufacturer’s instruc-
tions. The isolated RNA was  washed once with cold 75% ethanol,
dried and dissolved in diethylpyrocarbonate treated water before
use.
Reverse transcription and quantitative real-time PCR (RT-qPCR)
The reagents for gene expression analysis by real-time RT-PCR
were obtained from Applied Biosystems (Foster City, CA, USA).
500 ng of total RNA were reverse transcribed using random hex-
amers. RT-qPCR assay was carried out using gene-speciﬁc double
ﬂuorescently labeled probes. The primers and probes used to assay
the expression of -globin, -globin and mTOR mRNA were pur-
chased from IDT (Integrated DNA technologies, San Jose, CA, USA).
The nucleotide sequences used for real-time qPCR analysis of -
and -globin mRNAs and mTOR were as follows: -globin for-
ward primer, 5′-CAC GCG CAC AAG CTT CG-3′, -globin reverse
primer, 5′-AGG GTC ACC AGC AGG CAG T-3′, -globin probe, 5′-
FAM-TGG ACC CGG TCA ACT TCA AGC TCC T-TAMRA-3′; -globin
forward primer, 5′-TGG CAA GAA GGT GCT GAC TTC-3′, -globin
reverse primer, 5′-TCA CTC AGC TGG GCA AAG G-3′, -globin
probe, 5′-FAM-TGG GAG ATG CCA TAA AGC ACC TGG-TAMRA-3′;
mTOR forward primer 5′-GCT GTA CGT TCC TTC TCC TTC-3′, mTOR
reverse primer 5′-CAA GAA CTC GCT GAT CCA AAT G-3′, mTOR
probe, 5′-FAM-TGC ATT CCG-ZEN-ACC TTC TGC CTT CA-IABkFQ-
3′. The nucleotide sequences used for real-time qPCR analysis of
transferrin receptor and glycophorin A mRNAs were: transferrin
receptor forward primer, 5′-TCA GAGCGTCGGGATATCG-3′, trans-
ferrin receptor reverse primer, 5′-TGA ACT GCC  ACA CAG AAG
AAC A-3′, transferrin receptor probe 5′-FAM-TGG CGG  CTC GGG
ACG GA-TAMRA-3′; glycophorin A forward primer, 5′-CGG TAT
TCG CCG ACT GAT AAA-3′, glycophorin A reverse primer, 5′-AAA
GGC AGT CTG TGT CAG GT-3′, glycophorin A probe, 5′-FAM-AAA
GCC CAT CTG ATG TAA AAC CTC TTC CCC T-TAMRA-3′. The kit
for quantitative RT-PCR for -globin mRNA and -globin mRNA
were from Applied Biosystems (-globin mRNA: Hs00923579 m1;
-globin mRNA: Hs00362216 m1). The primers and probes used to
assay the expression of raptor mRNA (Assay ID Hs00977502 m1)
and for Rictor (Assay ID Hs.PT.56a.40621153.g) were purchased
from Applied Biosystems and from IDT, respectively. Relative
expression was  calculated using the comparative cycle thresh-
old method and the endogenous controls human 18S rRNA
(Assay ID 4310893E, Applied Biosystems) and RPL13A (Assay ID
Hs03043885 g1, Applied Biosystems) as reference genes. Dupli-
cate negative controls (no template cDNA) were also run with
every experimental plate to assess speciﬁcity and to rule out
contamination.
Western blotting
For extract preparation, MTH  treated or untreated K562 cells
were lysed in a ice cold RIPA buffer (10 mM Tris–HCl, pH 8.0, 0.5 mM
EDTA, 150 mM NaCl, 1% NP40, 0.1% SDS, 5 mg/ml  DeoxyCholic acid,
1 mM DTT, 2 mM PMSF, 2 mM Na3VO4, 10 mM  NaF, 1 g/ml Leu-
peptin, 1 g/ml Aprotinin). Brieﬂy, K562 cells (8 × 106 cells) were
collected and washed twice with cold PBS (Phosphate-Buffered
Saline, Lonza-Biowhittaker, Basel, Switzerland). Cellular pellets
were then suspended with 400 l of cold RIPA buffer, incubated
on ice for 20 min  and subjected to ﬁve cycles of freeze–thawing.
Samples were ﬁnally centrifuged at 14,000 × g for 3 min  at 4 ◦C and
the supernatant cytoplasmic fractions were collected and imme-
diately frozen at −80 ◦C. Protein concentration was determined
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sing PierceTM BCA Protein Assay Kit (Thermo Fisher Scientiﬁc,
ockford, USA). Ten g of cytoplasmic extracts were denatured for
 min  at 98 ◦C in 1× SDS sample buffer (62.5 mM Tris–HCl pH 6.8,
% SDS, 50 mM Dithiotreithol (DTT), 0.01% bromophenol blue, 10%
licerol) and loaded on SDS-PAGE gel (10 cm × 8 cm) in Tris-glycine
uffer (25 mM Tris, 192 mM glycine, 0.1% SDS). A biotinylated pro-
ein ladder (size range of 9–200 kDa) (Cat. 7071, Cell Signaling,
uroclone S.p.A., Pero, MI,  Italy) and/or a prestained multicolor
rotein ladder (size range 10–260 kDa) (Cat 26634, Thermo Fisher
cientiﬁc, Rockford, USA) were used as standards to determine
olecular weight. The electrotransfer to 0.2 m pore size nitro-
ellulose membrane (Pierce, Euroclone S.p.A., Pero, Milano, Italy)
as performed over-night at 360 mA  and 4 ◦C in electrotransfer
uffer (25 mM Tris, 192 mM Glycine, 5% methanol). The mem-
ranes were prestained with Ponceau S Solution (Sigma, St. Louis,
O,  USA) to verify the transfer, washed with 25 ml  TBS (10 mM
ris–HCl pH 7.4, 150 mM NaCl) for 10 min  at room temperature
nd incubated in 25 ml  of blocking buffer for 2 h at room temper-
ture. The membranes were washed three times for 5 min  each
ith 25 ml  of TBS/T (TBS, 0.1% Tween-20) and incubated with
he primary rabbit monoclonal antibody (1:1000) in 15 ml  pri-
ary antibody dilution buffer with gentle shaking over-night at
◦C. The next day, the membranes were washed three times for
 min  each with 20 ml  of TBS/T and incubated in 15 ml  of block-
ng buffer, with gentle shaking for 2 h at room temperature, with
n appropriate HRP-conjugated secondary antibody (1:2000) and
n HRP-conjugated anti-biotin antibody (1:1000) used to detect
iotinylated protein marker. Finally, after three washes each with
0 ml  of TBS/T for 5 min, the membranes were incubated with
0 ml  LumiGLO® (0.5 ml  20x LumiGLO®, 0.5 ml  20× Peroxide and
.0 ml  Milli-Q water) (Cell Signaling, Euroclone S.p.A., Pero, MI,
taly) with gentle shaking for 5 min  at room temperature and
xposed to x-ray ﬁlm (Pierce, Euroclone S.p.A., Pero, MI,  Italy). In
rder to re-probe the membranes, they were stripped using the
estoreTM Western Blot Stripping Buffer (Pierce, Euroclone S.p.A.,
ero, MI,  Italy) and incubated with other primary and secondary
ntibodies. The chemiluminescent signal was visualized on X-ray
lms and the intensity of the immunopositive bands was analyzed
y Gel Doc 2000 (Bio-Rad Laboratoires, MI,  Italy) using Quantity
ne program to elaborate the intensity data of our speciﬁc target
rotein.
reparation of nuclear extracts for bandshift and supershift assays
Nuclear extracts were prepared as described by Andrews and
aller [29]. Brieﬂy, cells were collected, washed twice with ice-
old phosphate-buffered saline, and suspended in 0.4 ml/107 cells
f hypotonic lysis buffer (10 mM Hepes/KOH, pH 7.9, 10 mM KCl,
.5 mM MgCl2, 0.5 mM dithiothreitol, and 0.2 mM phenylmethane-
ulfonyl ﬂuoride). After incubation on ice for 10 min, the mixture
as vortexed for 10 s, and nuclei were pelleted by centrifugation
t 12,000 × g for 10 s, then nuclear proteins were extracted by
ncubation of the nuclei for 20 min  on ice with intermittent gen-
le vortexing in 20 mM Hepes/KOH, pH 7.9, 25% glycerol, 420 mM
aCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM
henylmethanesulfonyl ﬂuoride, 1 g mL−1 aprotinin, 1 g mL−1
eupeptin, 2 mM Na3VO4, and 10 mM NaF (Sigma, St Louis, MO,
SA); cell debris was removed by centrifugation at 12,000 × g for
 min  at 4 ◦C. The BCA method was used to measure the protein
oncentration in the extract, which was then stored in aliquots at
80 ◦C.lectrophoretic mobility shift assays (EMSA)
The double-stranded oligonucleotides (ODN) used in the
MSA are reported in Table 1 [30]. 3 pmol of ODN wereResearch 91 (2015) 57–68 59
32P-labeled using OptiKinase (GE Healthcare, Chalfont St Giles, UK),
annealed to an excess of complementary ODN and puriﬁed from
[-32P]ATP (Perkin Elmer, Wellesley, MA,  USA). Binding reactions
were performed by incubating 2 g of nuclear extract and 16 fmol
of 32P-labeled double-stranded ODN, with or without competitor
in a ﬁnal volume of 20 L of binding buffer (20 mM Tris–HCl, pH
7.5, 50 mM KCl, 1 mM MgCl2, 0.2 mM EDTA, 5% glycerol, 1 mM
dithiothreitol, 0.01% TritonX100, 0.05 g L−1 of poly dI-dC,
0.05 g L−1 of a single-stranded ODN) [31]. Competitor (100 fold
excess of unlabeled ODNs) and nuclear extract mixture were incu-
bated for 15 min  and then probe was  added to the reaction. After
a further incubation of 30 min  at room temperature samples were
immediately loaded onto a 6% nondenaturing polyacrylamide gel
containing 0.25 × Tris/borate/EDTA (22.5 mM Tris, 22.5 mM boric
acid, 0.5 mM EDTA, pH 8) buffer. Electrophoresis was carried out at
200 V. Gels were vacuum heat-dried and subjected to autoradiog-
raphy. To verify the effects of mithramycin, DNA probes or nuclear
extracts, were preincubated for 1 h at 4 ◦C with different concen-
tration of the compound before the EMSA incubation. Supershift
assays were performed as described previously [31,32] by using
2 g of commercially available antibodies speciﬁc for Sp1 (cat.07-
645) transcription factor and anti-NF-kB (cat. 06–556) as a control
unrelated antibody (Upstate Biotechnology Inc., Lake Placid, NY,
USA).
Bio-Plex analysis
The levels of multiple transcription factors within nuclear
extracts obtained from stimulated cells were analyzed using the
Bio-Plex technology (Bio-Rad Laboratories, Hercules, CA) and the
BioSource’s Transcription Factor (TF) Assays (Biosource Inter-
national, Inc., California USA). Nuclear extracts were prepared
using BioSource’s Nuclear Extraction Kit (Biosource International,
Inc., California USA) and quantiﬁed using the Bradford assay.
The assay was performed as reported by the manufacturer.
Brieﬂy, biotin labeled DNA probes and controls or nuclear extract
samples were incubated for 20 min  at 25 ◦C in 96 well PCR
thermocycler-compatible microtiter plate. Subsequently Diges-
tion Reagent containing nuclease was  added to samples (except
positive control) for 20 min  at 37 ◦C. The ﬂuorescently encoded
microspheres conjugated to DNA sequences complementary to the
probes were then incubated with samples for 45 min  at room tem-
perature. Finally, the individual mixtures were transferred to the
wells of a ﬁlter plate, washed and incubated with streptavidin-
RPE. After the washing step the samples were analyzed in Bio-plex
instrument.
Transcription factor decoy (TFD) approach targeting Sp1 protein
binding on raptor promoter
The effect of the Sp1e consensus oligonucleotide decoy [33,34]
on raptor transcription was  evaluated by adding 2 g/ml of Sp1e
double-stranded oligonucleotide or a scrambled sequence of the
same length as a control (scramble ODN) (Table 1), and 4 g/ml
g/ml of lipofectamine 2000 to K562 cells seeded at 50–70% conﬂu-
ence in 16 mm  wells. Twenty-four hours later, RNA extraction and
reverse transcription were performed. Aliquots, 1/20 l of cDNA
were used for each SYBR Green realtime PCR reaction to quantify
the depletion of raptor transcripts, using the Raptor F primer and
the Raptor R reverse primer (Table 1) designed to amplify a 355 bp
sequence. Ampliﬁcation of human GAPDH cDNA served as an inter-
nal standard (housekeeping gene). Real-time PCR reactions were
performed for a total of 40 cycles (95 ◦C for 3 min, 66 ◦C for 30 s,
and 72 ◦C for 25 s). The CT method was  used to compare gene
expression data.
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Table 1
Double stranded syntetic oligonucleotides and PCR primers employed.
Name Method Ampliﬁed region Sequences
Sp1mera EMSA N.A.b 5′CCCTGGCCACGCCTCACTG3′
Sp1a EMSA N.A. 5′TGCACCACCACGCCTGGCCTCG3′
Sp1b EMSA N.A. 5′CACGCCACCACGCCCAGCTAAT3′
Sp1c EMSA N.A. 5′CGCACCACCACGCCCAGCTAAT3′
Sp1d EMSA N.A. 5′TTAGTAGGGACGGGGTTTCACC3′
Sp1e EMSA and decoy N.A. 5′TTTAATAACACGCCTCTACTGA3′
Sp1f EMSA N.A. 5′AGGTAACGGGGTCGGGGACTCTTTC3′
Sp1g EMSA N.A. 5′CTGTCGGCCACGCCGTAGGCCG3′
Asp ODN EMSA N.A. 5′TGTCGAATGCAATCACTAGAA3′
Scramble ODN Decoy N.A. 5′AGTCGTCACGTAAGTCGAGCAC3′
Raptor F Decoy real time PCR Raptor transcripts 5′CTGCAAGCATTCCAGGTGTG3′
Raptor R Decoy real time PCR Raptor transcripts 5′GTTCAGCTGGCATGTAGGGG3′
GAPDH Fc Decoy real time PCR GAPDH transcripts 5′AAGGTCGGAGTCAACGGATTT3′
GAPDH R Decoy real time PCR GAPDH transcripts 5′ACTGTGGTCATGAGTCCTTCCA3′
Raptor ChIP F ChIP real time PCR Raptor promoter 5′AACCGACAGTTTCATTTGTAGGATTG3′
Raptor ChIP R ChIP real time PCR Raptor promoter 5′AAACTCATCTCATCAGCCCATCA3′
Neg ChIP F ChiP real time PCR Negative control region 5′AGACAGGGTTTCACCATGTTGG3′
Neg ChIP R ChIP real time PCR Negative control region 5′GCCATAGCTAACTGCAGAGGACA3′
a Sp1 consensus sequence [30].
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c GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.
hromatin Immunoprecipitation Assays (ChIP)
Chromatin immunoprecipitation assays were performed using
he Chromatin Immunoprecipitation Assay Kit (Upstate Biotech-
ology) [31,35]. Brieﬂy, a total of 6 × 107 K562 cells, untreated
r treated with MTH  for 24 h, were incubated, for 10 min  at
oom temperature, with 1% formaldehyde culture medium. After
ashing in phosphate-buffered saline, glycine was added to a
nal concentration of 0.125 M.  The cells were then suspended in
.5 ml  of lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris–Cl,
H 8.1) plus protease inhibitors (1 g/ml pepstatin A, 1 g/ml
eupeptin, 1 g/ml aprotinin, and 1 mM phenylmethylsulfonyl ﬂu-
ride) and the chromatin subjected to sonication (using a Sonics
ibracell VC130 sonicator with a 2-mm probe). Fifteen 15-s son-
cation pulses at 30% amplitude were required to shear chromatin
o 200–1000 bp fragments. 0.2-ml aliquots of chromatin were
iluted to 2 ml  in ChIP dilution buffer containing protease inhibitors
nd then cleared with 75 l of salmon sperm DNA/protein A-
garose 50% gel slurry (Upstate Biotechnology) for 1 h at 4 ◦C before
ncubation on a rocking platform with either 6–10 g of spe-
iﬁc antiserum Sp1 (Upstate Biotechnology, cat.07-645) or normal
abbit serum. 20 l of diluted chromatin was saved and stored
or subsequent PCR analysis as 1% of the input extract). Incu-
ations occurred overnight at 4 ◦C and continued an additional
 h after the addition of 60 l protein A-agarose slurry. There-
fter the agarose pellets were washed consecutively with low salt,
igh salt and LiCl buffers. DNA/protein complexes were recov-
red from the pellets with elution buffer (0.1 M NaHCO3 with 1%
DS), and cross-links were reversed by incubating overnight at
5 ◦C with 0.2 M NaCl. The samples were treated with RNase A
nd proteinase K, extracted with phenol/chloroform and ethanol-
recipitated. The pelletted DNAs were washed with 70% ethanol
nd dissolved in 40 l of Tris/EDTA. 2 l aliquots were used for each
eal-time PCR reaction to quantitate immunoprecipitated promoter
ragments.
eal-time PCR quantiﬁcation of immunoprecipitated promoter
ragmentsFor quantitative real-time PCR reaction conditions each 25 l
eaction contained 2 l of template DNA (from chromatin immuno-
recipitations), 10 pmol of primers (Table 1) and 1× iQTM
YBR® Green Supermix (Bio-Rad). Real-time PCR reactions wereperformed for a total of 40 cycles (97 ◦C for 15 s, 65 ◦C for 30 s, and
72 ◦C for 30 s) using an iCycler IQ® (Bio-Rad). The relative propor-
tions of immunoprecipitated promoter fragments were determined
based on the threshold cycle (Tc) value for each PCR reaction.
Real-time PCR data analysis followed the methodology previ-
ously described [35–37]. A TC value was calculated for each
sample by subtracting the Tc value for the input (to account
for differences in ampliﬁcation efﬁciencies and DNA quantities
before immunoprecipitation) from the Tc value obtained for the
immunoprecipitated sample. Real-time PCR data analyses were
obtained using the comparative Ct method: a  Ct value was
calculated for each sample by subtracting the Ct value for the
sample ampliﬁed with raptor promoter primers from the Ct value
obtained for the same sample ampliﬁed with negative control
primers. For each kind of immunoprecipitation (IgG or Sp1 anti-
serum), a  Ct value was then calculated by subtracting the 
Ct value for the untreated cells sample from the Ct value for
the treated cell samples. Fold differences were then determined
by the 2−Ct method. Each sample was  quantiﬁed in duplicate
for at least three separate experiments. Mean ± SD values were
determined.
Cell cycle analysis
For ﬂow cytometric analysis of DNA content, 1 × 106 K562 cells
in exponential growth were treated with IC75 concentrations of the
tested compounds. After 72 h, the cells were centrifuged, washed
once with PBS, then treated with lysis buffer containing RNAse A,
NP40 0,1%, and ﬁnally stained with propidium iodide at 50 g/ml
(DNA QC particles, Becton Dickinson, Milan, Italy). Samples were
analyzed on a Becton Coulter Epics XL-MCL ﬂow cytometer. For cell
cycle analysis, DNA histograms were analyzed using MultiCycle®
for Windows (Phoenix Flow Systems, San Diego, CA).
Statistical analysis
All the data were normally distributed and presented as
mean ± SD. Statistical differences between groups were com-
pared using one-way ANOVA (ANalyses Of VAriance between
groups) software. P values were obtained using the Paired t
test of the GraphPad Prism Software. Statistical differences were
considered signiﬁcant when *p < 0.05, highly signiﬁcant when
**p < 0.01.
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Fig. 1. Effects of mithramycin (MTH) on erythroid induction and gene expression of K562 cells. A,B. Effects of 30 nM mithramycin on kinetics of
the  increase of the proportion of benzidine-positive cells (%) (average ± SD; number of independent experiments: 5) (A) and on the expression of -
globin,  -globin, -globin, -globin, transferrin receptor and glycophorin A genes evaluated by RT-qPCR of RNA isolated from K562 cells treated with
30  nM mithramycin for 5 days (B). MTH-treated samples of panel A are indicated with black circles). C,D. Effects of MTH on (A) -globin and
 cells. 
c e. The 
d
R
T
m
m
t
f
o
o
w
1
i
(-globin and (B) raptor, rictor and mTOR gene expression in MTH-treated K562 
les)  or in the presence (black circles) of 30 nM MTH  for the indicated length of tim
etermined by quantitative RT-PCR (average ± SD; n = 5).
esults
reatment of K562 cells with MTH  leads to inhibition of raptor
RNA accumulation, but not of rictor and mTOR mRNAs
To relate globin gene expression to that of genes involved in
-TORC1 and m-TORC2 pathways, mRNAs were studied by quan-
itative RT-PCR analysis using as template cytoplasmic RNA isolated
rom K562 cells cultured for different length of time in the absence
r in the presence of 30 nM MTH. In order to determine the extent
f erythroid induction, the proportion of benzidine-positive cells
as ﬁrstly measured (Fig. 1A) and was shown to be increased from
–5% (in control untreated cells) to 75–85% (in MTH-treated cells),
n agreement with previously published observations [26]. Fig. 1B
left side of the panel) shows that MTH  treatment induces, after 5RNA samples were obtained from K562 cells cultured in the absence (white cir-
data shown in panels B-D represent changes in gene expression referred to time 0,
days treatment, a large increase of (a) the -like -globin and -
globin mRNAs and (b) the -like -globin and -globin mRNAs.
These data conﬁrm that the MTH  mediated erythroid induction
was fully activated, sustaining the strong effect of MTH  as ery-
throid inducer of this cell line. The ongoing of the erythroid program
in MTH-induced K562 cells is also conﬁrmed by the increase of
other erythroid associated markers, including those encoded by
the CPOX (coproporphyrinogen oxidase), UROS (uroporphyrino-
gen III synthase), UROD (uroporphyrinogen decarboxylase), FECH
(ferrochelatase), NFE2L3 nuclear factor erythroid-derived 2-like 3),
EPB49 (erythrocyte membrane protein band 4.9), SLC4A1 (solute
carrier family 4, anion exchanger, member 1 erythrocyte mem-
brane protein band 3, Diego blood group) mRNAs (data not shown)
and transferrin receptor and glycophorin A mRNAs (Fig. 1B, right
side of the panel). Possible early changes in expression of genes
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Fig. 2. MTH  effects on raptor, rictor and mTOR in K562 cells. Western blotting analyses were performed on protein extracts obtained from K562 cells treated with 30 nM MTH
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tor  the indicated length of time, using raptor (A), rictor (B) and mTOR (C, upper pan
ntibodies. The relative expression values of samples from MTH  treated with respec
ower  part of the panels. Data represent the average ± SD; n = 3).
articipating to the mTOR pathway, such as raptor, rictor and
TOR, were then performed using RT-PCR analyses. Panel C of
ig. 1 shows the early increase of the levels of -globin and -
lobin mRNAs. Fig. 1D shows that (a) the content of raptor mRNA
harply decreases following MTH  treatment (left side of the panel)
nd (b) that this decrease occurs before the MTH-induced increase
f globin mRNAs (see Fig. 1, panel C). On the contrary, no inhibi-
ion of rictor mRNA and mTOR mRNA was detected (Fig. 1D, middle
nd right sides of the panel). These ﬁndings were fully supported
y the Western blotting analysis of cytoplasmic extracts isolated
rom K562 cells cultured for 24, 48 and 72 h with MTH, as reported
n Fig. 2. The results shown in Fig. 2A demonstrate a sharp inhi-
ition of raptor protein production following MTH  treatment. As
ar as rictor expression is concerned, no changes in its production
ere observed at 24 and 48 h, while after 72 h of treatment, a slight
ncrease was detectable (Fig. 2B). In addition, no changes in mTOR
ontent (Fig. 2C, upper part of the panel) was found in MTH treated
ells. Finally, no major changes were found in mTOR phosphoryla-
ion at Ser 2448 and Ser 2481 (Fig. 2C, middle and lower parts of
he panel).
These data demonstrate for the ﬁrst time strong inhibitory
ffects of mithramycin on mTORC1, but not on mTORC2. Accord-
ngly, the possible effects of mithramycin on the raptor gene
romoter were determined.
tructure of the raptor gene promoter
In order to identify putative regulatory regions located within
he raptor gene promoter, computer-aided analysis of the raptor
romoter sequence was performed with the aim to identify puta-
ive binding sites for transcription factors (Fig. 3A). Within the
1400/ + 1 promoter sequence, we identiﬁed homology to the fol-
owing transcription factor binding sites: LyF-1, AP1, C/EBP, USF,
ct, GATA-1 and at least twelve sequences 98–81% homologous
o the canonical 5′-CCT GGC CAC GCC TCA CTG-3′ Sp1 bindingmTOR (Ser2448) (C, middle panel), p-mTOR (Ser2481) (C, lower panel) monoclonal
ntreated cells were obtained from densitometric measurement and reported in the
site. Mithramycin has been widely reported as an antibiotic that
binds DNA exhibiting selective interactions with G + C rich regions,
demonstrated by computer modeling [38], Biacore analysis [20],
and DNase Footprinting [21]. As MTH  was  expected to affect
Sp1-DNA interactions as already reported [39–41], the in vitro inter-
actions of Sp1 with the raptor Sp1 binding sites present within the
raptor gene promoter were analyzed.
In vitro interaction of Sp1 transcription factor with the Sp1
binding sites of the raptor gene promoter: effects of MTH
To determine whether the raptor Sp1 binding sites are able to
interact with the Sp1 nuclear transcription factor, EMSA experi-
ments were carried out using 3 g of K562 nuclear extracts and
the raptor-Sp1 probes described in Fig. 3A and Table 1. The results
obtained are reported in Fig. 3B–E and indicate that the Sp1 probes
interact differently with K562 nuclear extracts. The speciﬁc com-
plexes generated by the interaction between nuclear extracts and
Sp1b, Sp1c, and Sp1e are arrowed in panels B-E of Fig. 3. The consen-
sus Sp1mer probes efﬁciently compete with the binding of nuclear
extracts to the consensus 32P-labeled Sp1mer probe (Fig. 3B), while
Sp1a, Sp1d, Sp1f and Sp1g were less efﬁcient in binding. Fig. 3C
shows a preliminary experiment demonstrating that Sp1e com-
petes, as Sp1mer, for Sp1/DNA interactions. Fig. 3D shows that Sp1e
is efﬁcient in competing with the binding of nuclear extracts to the
consensus 32P-labeled Sp1mer  probe. Fig. 3E shows that the binding
activity of Sp1e occurs also when puriﬁed Sp1 protein is employed.
Similar results were obtained with Sp1b and Sp1c oligonucleotides
(data not shown).
Sp1 transcription factor is involved in raptor gene expressionTo determine whether the Sp1 transcription factor might be
involved in raptor gene expression we  determined the extent of
Sp1 content in protein extracts from K562 cells using Bio-Plex
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Fig. 3. Schematic representation of raptor gene promoter and comparison between the binding efﬁciency of three Sp1 consensus sites. (A) Boxes indicate the Sp1 homology
binding sites. Nucleotide position and sequences (only for sites displaying homology ≥ 81%) are indicated. The length and position of the promoter fragment ampliﬁed in
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p1  consensus binding site Sp1mer (B, C, D, E) and Sp1e (C) oligonucleotide as probe
uantity of the competitor oligonucleotides as indicated.
ssays. Fig. 4A shows high content of Sp1 in K562 cells. It should
e pointed out however, that we have no evidence for the down
egulation of Sp1 in MTH-treated K562 cells (Fig. 4B). In order to
btain results clarifying a possible role of Sp1 in the regulation of
aptor gene expression a decoy experiment was performed, using a
reviously published protocol [34]. The results obtained show that
he decoy treatment using double stranded Sp1e oligonucleotide
nduces decrease of raptor mRNA content, suggesting a role of Sp1
n the control of raptor gene expression.
ffect of MTH  on in vitro interaction of Sp1 transcription factor
ith the Sp1 binding sites of the raptor gene promoter
Fig. 5 demonstrates that interaction of MTH  with Sp1e prevents
inding of nuclear extracts to the molecule (Fig. 5A, right side ofaptor ChIP R PCR primers. (B-E) Competitive bandshift assays performed using the
lear extracts from K562 cells (B, C, D) or recombinant Sp1 factor (E), and increasing
the panel). In addition, Fig. 5B (right side of the panel) shows that
the inhibitory effects of MTH  occur also on pre-formed Sp1-DNA
complexes. Both these MTH-mediated effects were similar to those
obtained using Sp1mer (Fig. 5A and B, left side of the panels). These
data clearly indicate that MTH  is able to inhibit the de novo interac-
tion of the Sp1 transcription factor within target Sp1 sequences, as
well as to disassemble preformed Sp1/DNA complexes. MTH treat-
ment of K562 cells may  therefore lead to sharp decreases of Sp1
transcription factor occupancy at the level of the raptor gene pro-
moter. In order to conclusively demonstrate that the transcription
factor Sp1 binds to Sp1e sequence, supershift experiments were
performed using monoclonal antibodies against Sp1 and nuclear
extracts from K562 cells. The addition of the antibody induces a
clear supershift (indicated in Fig. 5C with an arrowhead) showing
that Sp1 nuclear factor binds in vitro to the Sp1e probe. An antibody
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Fig. 4. Sp1 expression in K562 cells and effects of decoy molecules targeting Sp1 transcription factors. (A) Bio-Plex analysis of multiple transcription factors within nuclear
extracts  (expressed as ﬂuorescence intensity) obtained from untreated K562 cells. (B) Level of Sp1 transcription factor within nuclear extracts obtained from MTH treated
K562  cells for 0, 24, 48 and 72 h by Bio-plex technology. Data represent the average ± SD. (n = 3). (C) Effect of the Sp1e “decoy” ODN (gray box) or a scrambled unrelated
oligonucleotide (white box), on raptor mRNA levels. The cDNA obtained from total RNA was  subjected to quantitative real-time RT-qPCR for the raptor speciﬁc transcript.
Relative quantiﬁcation was calculated by the Ct method using untreated cells as control sample (value = 1). Data represent the average ± SD of triplicate experiments. p
values  were obtained using the Paired t test of the GraphPad Prism Software. Statistical signiﬁcance: *p < 0.05, signiﬁcant; **p < 0.01, highly signiﬁcant.
Fig. 5. MTH interferes with the interactions between Sp1 transcription factor and Sp1-sites of the raptor promoter sequences. (A,B) Bandshift assay was performed (A)
pre-incubating the probes with the indicated concentrations of MTH, then adding nuclear extracts or (B) pre-incubating the probes with nuclear extracts, then adding the
indicated increasing concentrations of MTH. (C) Supershift assay was  performed using Sp1e as probe and 4 g of nuclear extract from K562 cells; the probe was incubated
with  nuclear extracts in the absence (/) of antibody or in the presence of antibodies against Sp1 (Ab-Sp1) or NF-kB (Ab-NF-kB) factors. Arrows indicate the speciﬁc complexes
and  arrowhead indicates the super-shifted complexes.
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Fig. 6. MTH  inhibits in K562 cells the recruitment of Sp1 to the raptor gene promoter. (A,B) Characterization of the MTH-mediated effects on raptor gene expression analyzed
by  RT-qPCR (A) and by Western blotting (B). K562 cells were cultured for 24 h with the indicated concentrations of MTH  for RT-qPCR, while protein expression was analyzed
in  extracts from K562 cells cultured with 15 and 30 nM MTH for 24 and 48 h, as indicated. (C) Quantitative real-time PCR proﬁles for the ampliﬁcation of raptor promoter from
a  representative ChIP assay in which chromatin from K562 cells was immunoprecipitated using Sp1 antiserum. Input, genomic DNA without antibodies addition; Sp1ChIP,
ChIP  performed with the Sp1 monoclonal antibody; Igg ChIP, control ChIP with non-immune serum. The data demonstrate the early exponential increase in ﬂuorescence
as  a result of SYBR Green I incorporation into the amplifying raptor promoter fragment. (D) In vivo association of Sp1 transcription factor with raptor promoter obtained
from  ChIP experiment on K562 cells treated with 15 and 30 nM MTH. The results, obtained from ChIP assay quantitative real-time PCR using negative control IgG and Sp1
antiserum, were analyzed following the methodology described in Section ‘Materials and methods’. The fold decrease compares the values obtained by raptor gene promoter
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 values were obtained using the Paired t test of the GraphPad Prism Software. Stat
gainst NF-kB failed to induce supershift (Fig. 5C, left row). Chro-
atin immunoprecipitation was performed to verify the effects of
TH on this binding activity in an in vivo context.
hromatin immunoprecipitation (ChIP) analysis
Chromatin immunoprecipitation (ChIP) assays were performed
n K562 cells either untreated, or treated with MTH to characterize
he MTH  effects on Sp1 function in intact cells. An RT-qPCR based
tudy of the effects on raptor gene expression of different MTH
oncentrations (Fig. 6A) was conducted prior to performing ChIP.
his treatment was performed for 24 h and demonstrated a con-
entration dependent inhibitory activity of MTH, suggesting that
5 nM and 30 nM concentrations might be suitable for ChIP assay.
n parallel, the effects of 15 nM and 30 nM MTH  treatments on rap-
or production were assessed using Western blotting on protein
xtracts isolated after 24 and 48 h from MTH-treated cells (Fig. 6B).
hiP was performed on K562 cells treated for 24 h with 15 nM and
0 nM MTH. Chromatin was immunoprecipitated using Sp1 anti-
erum and quantitative ampliﬁcation of raptor gene promoter wasta reported in panels A and D represent the average ± SD of triplicate experiments.
 signiﬁcance: *p < 0.05, signiﬁcant; **p  < 0.01, highly signiﬁcant.
performed on puriﬁed DNA. A representative ChIP assay is shown in
Fig. 6C, in which it is clearly evident that ampliﬁcation curves from
samples immunoprecipitated with Sp1 antisera (Sp1 ChIP) reach
threshold 5 cycles early than those treated with non immune serum
(Igg ChIP). Fig. 6D shows that raptor-speciﬁc PCR is less efﬁcient
when samples from MTH-treated cells are employed, suggesting
that MTH  dose-dependently inhibits the recruitment of Sp1 to the
raptor gene promoter.
MTH treatment is associated with inhibition of mTORC1 regulated
biological process
In order to obtain a ﬁnal proof of principle sustaining that the
raptor/mTOR network is involved in MTH  effects, biological param-
eters downstream from mTOR were considered [42–46]. K562
cells were treated with 30 nM MTH  and the expression levels of
mTORC1-regulated p70S6 kinase analyzed. The results are shown
in Fig. 7A, and clearly sustain the concept that MTH  inhibits the
phosphorylation of p70S6 kinase. Fig. 7B shows the involvement
of p70S6 kinase on the cell cycle [43,45], and demonstrates that
MTH  treatment of K562 cells leads to an increase of G1-phase cells,
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Fig. 7. Effects of MTH  on p70S6 kinase and cell cycle. (A) Western blotting analysis was  performed on protein extracts obtained from K562 cells treated with 30 nM MTH  for
the  indicated length of time, using p70 and p-p70 (Thr389) monoclonal antibody. Densitometric values indicating the relative p-p70 (Thr389) phosphorylation are reported
in  the lower part of panel A. (B) Representative histograms of ﬂow cytometry data of untreated control K562 cells (upper panel), K562 cells treated for 3 days (middle panel)
or  4 days (lower panel) with 30 nM MTH  (IC50). After 3 or 4 days of incubation the cells were labeled with propidium iodide and analyzed by ﬂow cytometry as described in
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Section  ‘Materials and Methods’. Data reported in panel A represents the average ±
**p  < 0.01).
n association with a sharp decrease of the proportion of S-phase
ells.
iscussion
This study investigated the possible effects of mithramycin,
nown to be a strong inducer of fetal hemoglobin in erythroid cells
rom normal and -thalassmic patients, on the mTOR pathway.
he involvement of the mTOR pathway in erythroid differentia-
ion is sustained by the ﬁnding that rapamycin, an inhibitor of
TOR activity is a potent inducer of erythroid differentiation of
uman leukemic K562 cells [18] and fetal hemoglobin production
y -thalassemic patients [19].
Of the major classes of mRNAs involved in the mTOR path-
ay (mTOR, rictor and raptor), the expression of raptor mRNA is
trongly reduced by mithramycin treatment. The mechanism of
ction leading to this effect was studied via the promoter sequence
f the raptor gene revealing several Sp1 binding sites. These tran-
cription factors are highly expressed in K562 cells and expression
oes not change following MTH  treatment. Its role in raptor gene
xpression is sustained by the ﬁnding that treatment of K562
ells with decoy molecules mimicking the Sp1-e site of the rap-
or gene promoter leads to raptor mRNA decrease (see Fig. 4).
he hypothesis that one of the mechanisms of action of the G + C-
elective DNA-binding drug mithramycin is the interaction with
p1-like sequences causing inhibition of the binding of Sp1 with= 3). P values were obtained using the Paired t-test of the GraphPad Prism Software
the raptor promoter in target cells is supported by the following
results: (a) MTH  strongly inhibits the interactions between Sp1 and
Sp1-binding sites of the raptor promoter (EMSA assays); (b) MTH
strongly reduces the recruitment of Sp1 transcription factor to the
raptor promoter in intact K562 cells (ChIP experiments. A sharp
decrease of p70S6 kinase phosphorylation and cell cycle alterations
were reproducibly detectable in mithramycin treated K562 cells in
agreement with the hypothesis that MTH  inhibits, through raptor
decrease, the mTORC1 activity.
This study does not allow us to conclude that inhibition of
mTOC1 is required for erythroid differentiation, but simply that
this issue deserves to be further investigated, as mTOR is expressed
at high levels in erythrocytes [47]. On the other hand, the mTOR
inhibitors rapamycin [18,19] and its analog everolimus [48] are
strong inducers of erythroid differentiation of K562 cells and HbF
induction in erythroid precursor cells of -thalassemia patients.
One possible explanation of this apparent discrepancy is that
changes of mTOR activity can be associated to speciﬁc stages
of erythroid differentiation, with signiﬁcant differences between
early and late/terminal stages of differentiation. Furthermore, the
decrease of mTOR activity might be linked, instead to the over-
all erythroid phenotype, only to some erythroid features leading
to high expression of embryo-fetal globin genes. In addition to
changes at the transcriptional control level, translational control
might also be involved both in activation of erythroid pathways,
and the regulation of the expression of -globin genes [49,50]. This
ogical 
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peciﬁc issue was not addressed by the present study. However,
ypoxia, a condition stimulating HbF in erythroid cells [51], is also
ssociated with the decrease of mTORC1 activity [52] and alteration
f the control of protein synthesis [53].
Whilst we cannot exclude additional mechanism(s) of action,
he results reported here suggest that one of the biological effects
f mithramycin might be the inhibition of Sp1 binding to the rap-
or gene promoter. In order to extend this observation to other
rythroid cellular system, further research should be focused on
rythroid precursor cells from normal subjects and -thalassemia
atients. Mithramycin has been proposed not only as inducer of
bF in thalassemic cells [26], but also as anti-tumor drug in can-
er cells [54,55]. Therefore, our study might be of interest in the
eld of mechanism of action of anti-tumor compounds. Finally,
he understanding of the mechanism of action of mithramycin
ight retain practical application in applied biomedicine. In fact,
iochemical targets of MTH  action (for instance raptor and Sp1)
ight be themselves novel biomolecular targets of therapeutic
ntervention based on more selective agents (such as antisense and
hRNA molecules targeting mRNAs, or double stranded molecules
argeting transcription factors). Interestingly, limiting this consid-
rations to erythroid cells, the mTOR inhibitors rapamycin and
verolimus are potent inducers of HbF in erythroid precursor
ells from -thalassemia patients [19,48] and RNAi-mediated Sp1
nockout induces high level of hemoglobinization in K562 cells
56].
onclusions
This study presents evidence supporting the concept that
lteration of raptor gene expression occurs during mithramycin-
ediated induction of erythroid differentiation of K562 cells. One
f the mechanisms of action of mithramycin is the inhibition of
p1 binding to the raptor promoter, thereby strongly inhibiting
he transcription of the raptor gene. In association with the MTH-
ediated down-regualtion of raptor, mTORC1 associated functions
uch as p70S6 kinase phosporilation and cell cycle parameters were
lso altered.
uthors contributions
AF and RG participated in research design; NB, AF and JG con-
ucted K562 cell culture; AF and GB performed EMSA experiments
nd conducted Sp1 decoy experiments; AF conducted Chromatin
mmunoprecipitation experiments; MB  performed Bio-plex exper-
ments; AF, NB and EF conducted RT-PCR analyses; EF, GB and JG
onducted FACS experiments; NB and AF performed Western blot-
ing experiments; AF, NB and MB analyzed data; AF, RG and JG
rote or contributed to the writing of the manuscript.
onﬂict of interest
The authors declare no competing ﬁnancial interests.
cknowledgements
Roberto Gambari is funded by Fondazione Cariparo (Cassa di
isparmio di Padova e Rovigo, grant n.2011), UE FP7 THALAMOSS
roject (Thalassemia Modular Stratiﬁcation System for Personal-
zed Therapy of ß-Thalassemia, grant n.306201), Telethon (grant
.GGP10124). This research activity was also supported by Associ-
zione Veneta per la Lotta alla Talassemia (AVLT, grant n.2013) and
y AIRC 2012 (grant n. IG 13575).
We  would like to thank Dr Amanda Julie Neville MSB  for her
nvaluable help in revising the scientiﬁc English of the manuscript.
[Research 91 (2015) 57–68 67
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.phrs.2014.11.005.
References
[1] Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev
2004;18(16):1926–45, http://dx.doi.org/10.1101/gad.1212704.
[2] Bracho-Valdés I, Moreno-Alvarez P, Valencia-Martínez I, Robles-Molina E,
Chávez-Vargas L, Vázquez-Prado J. mTORC1- and mTORC2-interacting proteins
keep their multifunctional partners focused. IUBMB Life 2011;63(10):896–914,
http://dx.doi.org/10.1002/iub.558.
[3] Oh WJ,  Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle
2011;10(14):2305–16, http://dx.doi.org/10.4161/cc.10.14.16586.
[4] Weber JD, Gutmann DH. Deconvoluting mTOR biology. Cell Cycle
2012;11(2):236–48, http://dx.doi.org/10.4161/cc.11.2.19022.
[5]  Weichhart T. Mammalian target of rapamycin: a signaling kinase
for every aspect of cellular life. Methods Mol Biol 2012;821:1–14,
http://dx.doi.org/10.1007/978-1-61779-430-8 1.
[6]  Kim D, Sarbassov D, Ali S, King J, Latek R, Erdjument-Bromage H,
et  al. mTOR interacts with raptor to form a nutrient-sensitive com-
plex that signals to the cell growth machinery. Cell 2002;110(2):163–75,
http://dx.doi.org/10.1016/S0092-8674(02)00808-5.
[7]  Kim D, Sarbassov D, Ali S, Latek R, Guntur K, Erdjument-Bromage H, et al.
GL, a positive regulator of the rapamycin-sensitive pathway required
for  the nutrient-sensitive interaction between raptor and mTOR. Mol  Cell
2003;11(4):895–904, http://dx.doi.org/10.1016/S1097-2765(03)00114-X.
[8] Fang Y, Vilella-Bach M,  Bachmann R, Flanigan A, Chen J. Phospha-
tidic acid-mediated mitogenic activation of mTOR signaling. Science
2001;294(5548):1942–5, http://dx.doi.org/10.1126/science.1066015.
[9] Yan L, Lamb RF. Amino acid sensing and regulation of mTORC1. Semin Cell Dev
Biol 2012;23(6):621–5, http://dx.doi.org/10.1016/j.semcdb.2012.02.001.
10] Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD. A growing role for mTOR
in  promoting anabolic metabolism. Biochem Soc Trans 2013;41(4):906–12,
http://dx.doi.org/10.1042/BST20130041.
11] Laplante M,  Sabatini DM. Regulation of mTORC1 and its impact
on gene expression at a glance. J Cell Sci 2013;126(8):1713–9,
http://dx.doi.org/10.1242/jcs.125773.
12] Cybulski N, Hall MN.  TOR complex 2: a signaling pathway of its own. Trends
Biochem Sci 2009;34(12):620–7, http://dx.doi.org/10.1016/j.tibs.2009.09.004.
13]  Huang J, Manning BD. A complex interplay between Akt, TSC2 and
the  two  mTOR complexes. Biochem Soc Trans 2009;37(1):217–22,
http://dx.doi.org/10.1042/BST0370217.
14] Sarbassov D, Ali S, Kim D, Guertin D, Latek R, Erdjument-Bromage H, et al.
Rictor, a novel binding partner of mTOR, deﬁnes a rapamycin-insensitive
and  raptor-independent pathway that regulates the cytoskeleton. Curr Biol
2004;14(14):1296–302, http://dx.doi.org/10.1016/j.cub.2004.06.054.
15] Sarbassov D, Guertin D, Ali S, Sabatini D. Phosphorylation and regulation
of  Akt/PKB by the rictor-mTOR complex. Science 2005;307(5712):1098–101,
http://dx.doi.org/10.1126/science.1106148.
16] Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter G,
Holmes A, et al. Protein kinase B kinases that mediate phosphatidylin-
ositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science
1998;279(5351):710–4, http://dx.doi.org/10.1126/science.279.5351.710.
17] Sarbassov D, Ali S, Sengupta S, Sheen J, Hsu P, Bagley A, et al. Prolonged
rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol  Cell
2006;22(2):159–68, http://dx.doi.org/10.1016/j.molcel.2006.03.029.
18] Mischiati C, Sereni A, Lampronti I, Bianchi N, Borgatti M,  Prus E,
et  al. Rapamycin-mediated induction of gamma-globin mRNA accumu-
lation in human erythroid cells. Br J Haematol 2004;126(4):612–21,
http://dx.doi.org/10.1111/j. 1365-2141.2004.05083.x.
19] Fibach E, Bianchi N, Borgatti M,  Zuccato C, Finotti A, Lampronti I, et al.
Effects of rapamycin on accumulation of alpha-, - and gamma-globin mRNAs
in  erythroid precursor cells from -thalassaemia patients. Eur J Haematol
2006;77(5):437–41, http://dx.doi.org/10.1111/j. 1600-0609.2006.00731.x.
20]  Gambari R, Feriotto G, Rutigliano C, Bianchi N, Mischiati C. Biospeciﬁc interac-
tion analysis (BIA) of low-molecular weight DNA-binding drugs. J Pharmacol
Exp  Ther 2000;294(1):370–7.
21] Bianchi N, Osti F, Rutigliano C, Corradini FG, Borsetti E, Tomassetti M,
et  al. The DNA-binding drugs mithramycin and chromomycin are power-
ful inducers of erythroid differentiation of human K562 cells. Br J Haematol
1999;104(2):258–65, http://dx.doi.org/10.1046/j. 1365-2141.1999.01173.x.
22] Gambari R, Fibach E. Medicinal chemistry of fetal hemoglobin induc-
ers for treatment of -thalassemia. Curr Med  Chem 2007;14(2):199–212,
http://dx.doi.org/10.2174/092986707779313318.
23] Carpenter ML,  Cassidy SA, Fox KR. Interaction of mithramycin
with isolated GC and CG sites. J Mol Recognit 1994;7(3):189–97,
http://dx.doi.org/10.1002/jmr.300070306.
6 ogical
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
http://dx.doi.org/10.1111/cbdd.12107.8 A. Finotti et al. / Pharmacol
24] Carpenter ML,  Marks JN, Fox KR. DNA-sequence binding preference of the
GC-selective ligand mithramycin. Deoxyribonuclease-I/deoxyribonuclease-
II and hydroxy-radical footprinting at CCCG, CCGC, CGGC, GCCC and
GGGG ﬂanked by (AT)n and An.Tn. Eur J Biochem 1993;215(3):561–6,
http://dx.doi.org/10.1111/j. 1432-1033.1993.tb18066.x.
25] Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee IN, et al. Novel GC-rich
DNA-binding compound produced by a genetically engineered mutant of the
mithramycin producer Streptomyces argillaceus exhibits improved transcrip-
tional repressor activity: implications for cancer therapy. Nucleic Acids Res
2006;34(6):1721–34, http://dx.doi.org/10.1093/nar/gkl063.
26] Fibach E, Bianchi N, Borgatti M,  Prus E, Gambari R. Mithramycin
induces fetal hemoglobin production in normal and thalassemic
human erythroid precursor cells. Blood 2003;102(4):1276–81,
http://dx.doi.org/10.1182/blood-2002-10-3096.
27] Lozzio BB, Lozzio CB. Properties of the K562 cell line derived from
a  patient with chronic myeloid leukemia. Int J Cancer 1977;19(1):136,
http://dx.doi.org/10.1002/ijc.2910180405.
28] Lampronti I, Bianchi N, Zuccato C, Dall’acqua F, Vedaldi D, Viola G,
et  al. Increase in gamma-globin mRNA content in human erythroid
cells treated with angelicin analogs. Int J Hematol 2009;90(3):318–27,
http://dx.doi.org/10.1007/s12185-009-0422-2.
29] Andrews NC, Faller DV. A rapid micropreparation technique for extraction
of  DNA-binding proteins from limiting numbers of mammalian cells. Nucleic
Acids Res 1991;19:2499, http://dx.doi.org/10.1093/nar/19.9.2499.
30] Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M,  Bianchi N, et al.
Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-
DNA chimera mimicking Sp1binding sites. J Biol Chem 2002;278(9):7500–9,
http://dx.doi.org/10.1074/jbc.M206780200.
31] Finotti A, Treves S, Zorzato F, Gambari R, Feriotto G. Upstream stimulatory fac-
tors  are involved in the P1 promoter directed transcription of the A  H-J-J
locus. BMC  Mol  Biol 2008;9:110, http://dx.doi.org/10.1186/1471-2199-9-110.
32]  Feriotto G, Finotti A, Volpe P, Treves S, Ferrari S, Angelelli C, et al. Myocyte
enhancer factor 2 activates promoter sequences of the human AH-J-J
locus, encoding aspartyl--hydroxylase, junctin, and junctate. Mol  Cell Biol
2005;25:3261–75, http://dx.doi.org/10.1128/MCB.25.8. 3261-3275.2005.
33] Feriotto G, Finotti A, Breveglieri G, Treves S, Zorzato F, Gambari R. Trans-
criptional activity and Sp 1/3 transcription factor binding to the P1
promoter sequences of the human AH-J-J locus. FEBS J 2007;274:4476–90,
http://dx.doi.org/10.1111/j. 1742-4658.2007.05976.x.
34] Finotti A, Borgatti M,  Bezzerri V, Nicolis E, Lampronti I, Dechecchi M,  et al.
Effects of decoy molecules targeting NF-kappaB transcription factors in Cys-
tic  ﬁbrosis IB3-1 cells: recruitment of NF-kappaB to the IL-8 gene promoter
and transcription of the IL-8 gene. Artif DNA PNA XNA 2012;3(2):97–296,
http://dx.doi.org/10.4161/adna.21061.
35] Bezzerri V, Borgatti M,  Finotti A, Tamanini A, Gambari R, Cabrini
G.  Mapping the transcriptional machinery of the IL-8 gene in
human bronchial epithelial cells. J Immunol 2011;187(11):6069–81,
http://dx.doi.org/10.4049/jimmunol.1100821.
36] Chakrabarti SK, James JC, Mirmira RG. Quantitative assessment of gene tar-
geting in vitro and in vivo by the pancreatic transcription factor, Pdx1.
Importance of chromatin structure in directing promoter binding. J Biol Chem
2002;277(15):13286–93, http://dx.doi.org/10.1074/jbc.M111857200.
37] Christenson LK, Stouffer RL, Strauss 3rd JF. Quantitative analysis of
the hormone-induced hyperacetylation of histone H3 associated with
the  steroidogenic acute regulatory protein gene promoter. J Biol Chem
2001;276(29):27392–9, http://dx.doi.org/10.1074/jbc.M101650200.38]  Sastry M,  Fiala R, Patel DJ. Solution structure of mithramycin dimers bound
to  partially overlapping sites on DNA. J Mol  Biol 1995;251(5):674–89,
http://dx.doi.org/10.1006/jmbi.1995.0464.
39] Fernández-Guizán A, Mansilla S, Barceló F, Vizcaíno C, Nún˜ez LE, Morís F, et al.
The activity of a novel mithramycin analog is related to its binding to DNA,
[ Research 91 (2015) 57–68
cellular accumulation, and inhibition of Sp1-driven gene transcription. Chem
Biol Interact 2014;219C:123–32, http://dx.doi.org/10.1016/j.cbi.2014.05.019.
40] Malek A, Nún˜ez LE, Magistri M,  Brambilla L, Jovic S, Carbone GM,  et al. Mod-
ulation of the activity of Sp transcription factors by mithramycin analogues
as  a new strategy for treatment of metastatic prostate cancer. PLoS ONE
2012;7(4):e35130, http://dx.doi.org/10.1371/journal.pone.0035130.
41] Sleiman SF, Langley BC, Basso M,  Berlin J, Xia L, Payappilly JB, et al. Mithramycin
is  a gene-selective Sp1 inhibitor that identiﬁes a biological intersection
between cancer and neurodegeneration. J Neurosci 2011;31(18):6858–70,
http://dx.doi.org/10.1523/JNEUROSCI. 0710-11.2011.
42] Bahrami-BF, Ataie-Kachoie P, Pourgholami MH,  Morris DL. p70 Ribo-
somal protein S6 kinase (Rps6kb1): an update. J Clin Pathol 2014,
http://dx.doi.org/10.1136/jclinpath-2014-202560.
43] Korta DZ, Tuck S, Hubbard EJ. S6K links cell fate, cell cycle and nutrient response
in  C. elegans germline stem/progenitor cells. Development 2012;139(March
(5)):859–70, http://dx.doi.org/10.1242/dev.074047.
44] Santi SA, Lee H. Ablation of Akt2 induces autophagy through cell
cycle arrest, the downregulation of p70S6K, and the deregulation
of mitochondria in MDA-MB231 cells. PLoS ONE 2011;6(1):e14614,
http://dx.doi.org/10.1371/journal.pone.0014614.
45] Yellen P, Chatterjee A, Preda A, Foster DA. Inhibition of S6 kinase
suppresses the apoptotic effect of eIF4E ablation by inducing TGF-
-dependent G1 cell cycle arrest. Cancer Lett 2013;333(2):239–43,
http://dx.doi.org/10.1016/j.canlet.2013.01.041.
46] Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6
kinase (S6K) within mTOR signalling networks. Biochem J 2012;441(1):1–21,
http://dx.doi.org/10.1042/BJ20110892.
47] Knight ZA, Schmidt SF, Birsoy K, Tan K, Friedman JM.  A critical
role for mTORC1 in erythropoiesis and anemia. Elife 2014;8(3):e01913,
http://dx.doi.org/10.7554/eLife.01913.
48] Zuccato C, Bianchi N, Borgatti M,  Lampronti I, Massei F, Favre C, Gambari R.
Everolimus is a potent inducer of erythroid differentiation and gamma-globin
gene expression in human erythroid cells. Acta Haematol 2007;117(3):168–76,
http://dx.doi.org/10.1159/000097465.
49] Hu W,  Yuan B, Lodish HF. Cpeb4-mediated translational regulatory cir-
cuitry controls terminal erythroid differentiation. Dev Cell 2014;30(6):660–72,
http://dx.doi.org/10.1016/j.devcel.2014.07.008.
50] Hahn CK, Lowrey CH. Induction of fetal hemoglobin through enhanced
translation efﬁciency of -globin mRNA. Blood 2014;124(17):2730–4,
http://dx.doi.org/10.1182/blood-2014-03-564302.
51] Salomon-Andonie J, Miasnikova G, Sergueeva A, Polyakova LA, Niu X, Nekhai
S,  et al. Effect of congenital upregulation of hypoxia inducible factors on
percentage of fetal hemoglobin in the blood. Blood 2013;122(17):3088–9,
http://dx.doi.org/10.1182/blood-2013-07-515973.
52] Vadysirisack DD, Ellisen LW.  mTOR activity under hypoxia. Methods Mol  Biol
2012;821:45–58, http://dx.doi.org/10.1007/978-1-61779-430-8 4.
53] Gorospe M,  Tominaga K, Wu X, Fähling M,  Ivan M.  Post-Transcriptional Control
of  the Hypoxic Response by RNA-Binding Proteins and MicroRNAs. Front Mol
Neurosci 2011;4:7, http://dx.doi.org/10.3389/fnmol.2011.00007.
54] Shin JA, Jung JY, Ryu MH,  Safe S, Cho SD. Mithramycin A inhibits myeloid
cell  leukemia-1 to induce apoptosis in oral squamous cell carcinomas and
tumor xenograft through activation of Bax and oligomerization. Mol Pharmacol
2013;83(1):33–41, http://dx.doi.org/10.1124/mol.112.081364.
55] Scott D, Chen JM, Bae Y, Rohr J. Semi-synthetic mithramycin SA derivatives
with improved anticancer activity. Chem Biol Drug Des 2013;81(5):615–24,56] Hu JH, Navas P, Cao H, Stamatoyannopoulos G, Song CZ. Systematic
RNAi studies on the role of Sp/KLF factors in globin gene expres-
sion and erythroid differentiation. J Mol  Biol 2007;366:1064–73,
http://dx.doi.org/10.1016/j.jmb.2006.12.047.
